4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001209191-21-025119
Director sold 50,000 shares at an average $56.62 ($2,831,071)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Tessier-Lavigne Marc Director | 2021-04-01 | Sale | −14,223 | $55.61 | $790,884 | 2,628,073 | D |
| Tessier-Lavigne Marc Director | 2021-04-01 | Sale | −29,593 | $56.91 | $1,684,019 | 2,598,480 | D |
| Tessier-Lavigne Marc Director | 2021-04-01 | Sale | −6,184 | $57.60 | $356,167 | 2,592,296 | D |
| Open-market sales · 50,000 sh · avg $56.62 · $2,831,071 | |||||||
Loading xslF345X03/doc4.xml…